Bright Peak Therapeutics AG

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

In a time when biotechs are finding it tough to raise funds, Alentis Therapeutics has topped up its already-sizeable cash pile with the addition of a couple of heavyweight healthcare investors to ad

Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel

After a couple of decades of research, Alentis Therapeutics is close to advancing its anti-fibrotic molecules into the clinic, armed with $67m of new funding. Alentis, a Switzerland-based biotech, i